Mortality Reduction After Oral Azithromycin: Morbidity Study
Status:
Completed
Trial end date:
2020-08-27
Target enrollment:
Participant gender:
Summary
The long-term goal of this study is to more precisely define the role of mass azithromycin
treatments as an intervention for reducing childhood morbidity and increasing growth, and for
the potential selection of antibiotic resistance. The investigators propose a set of 3
cluster-randomized trials in Malawi, Niger, and Tanzania comparing communities randomized to
oral azithromycin with those randomized to placebo. To assess the generalizability of the
intervention, investigators will monitor for antibiotic resistance, which could potentially
limit adoption of mass antibiotic treatments. The investigators will also assess several
measures of infectious diseases. The investigators hypothesize that mass azithromycin
treatments will reduce childhood morbidity and will be accompanied by an acceptable level of
antibiotic resistance.
Phase:
Phase 4
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
Bill and Melinda Gates Foundation Johns Hopkins University London School of Hygiene and Tropical Medicine